Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Biogen submits nusinersen NDA

September 26, 2016 7:00 AM UTC

Biogen Inc. (NASDAQ:BIIB) completed submission of a rolling NDA to FDA for nusinersen ( IONIS-SMNRx) to treat spinal muscular atrophy (SMA). The company requested Priority Review for nusinersen, an antisense oligonucleotide that modulates splicing of survival of motor neuron 2 centromeric ( SMN2) mRNA.

Last month, Biogen exercised an exclusive option to obtain worldwide rights to nusinersen after Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said the therapy met a co-primary endpoint in the Phase III ENDEAR study to treat infantile-onset SMA (see BioCentury Extra, Aug. 1). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article